Safelia® autoinjector is selected as finalist for the ‘Excellence in Pharma: Drug Delivery Devices’ CPhI Pharma Awards


Nemera-Finalist CPhI Awards-rond

Nemera has been selected as finalist at CPhI Awards for the ‘Excellence in Pharma: Drug Delivery Devices” category for Safelia®, its new generation of 2-steps autoinjector for fluid and viscous formulations.

Safelia® is an innovative autoinjector, declined in 1ml and 2.25m platforms for prefilled syringes, able to administer high volumes, high viscosities and through thinner needles.

It has been designed to ease patient self-injection experience and to deliver, in glass syringes, fluid formulations to challenging drugs (viscous, sustain released, concentrated, in subcutaneous or intramuscular layers, in large volumes…).

safelia 1ml and 2,25_range_web

Key benefits of Safelia®

Patient friendly

  • No initial injection peak
  • Constant delivery flow
  • Adjustable needle insertion speed
  • Needle insertion disconnected from injection
  • Automatic needle retraction
  • Possibility to have thinner needles

Syringe friendly

  • Syringe is held encapsulated through the barrel
  • Syringe front housing
  • No stress on the syringe flange
  • Possibility to inject very viscous drugs

You can discover Safelia® during CPhI Worldwide (booth 2M38), which is taking place in Barcelona, on October 4th-6th.

About Nemera

Nemera is a world leader in the design, development and manufacturing of drug delivery solutions. Its expertise covers several modes of delivery: Parenteral (autoinjectors, pens, and safety devices), Nasal/Buccal/Auricular (spray pumps, actuators, valves, etc.), Ophthalmic (preservative-free multidose eyedroppers), Pulmonary (pMDI, MDI’s, DPI’s) and Dermal /Transdermal (airless & atmospheric dispensers).
Nemera provides solutions for the pharmaceutical industry, including standard innovative products, the development of proprietary devices and contract manufacturing.